Real‐world insights into risk of developing cardiovascular disease following Gn RH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases-Reference-Cited by-同舟云学术

Real‐world insights into risk of developing cardiovascular disease following Gn RH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases

Published:2019-03-25 Issue:4 Volume:33 Page:479-499
ISSN:0767-3981
Container-title:Fundamental & Clinical Pharmacology
language:en
Short-container-title:Fundam Clin Pharmacol

Author:

George Gincy¹^ORCID,Scailteux Lucie‐Marie²³^ORCID,Garmo Hans¹,Balusson Frédéric³,Cardwell Christopher⁴,Coster Greet De⁵,Schutter Harlinde De⁵,Kuiper Josephina G.⁶,McMenamin Úna⁴,Verbeeck Julie⁵,Van Hemelrijck Mieke¹

Affiliation:

1. Translational Oncology and Urology Research King's College London London UK

2. Pharmacovigilance, Pharmacoepidemiology and Drug Information Center Rennes Hospital University Rennes France

3. REPERES (Pharmacoepidemiology and Heath Services Research) Rennes University EA 7449, F‐35000 RennesFrance

4. Centre for Public Health Institute for Health Sciences Queen's University Belfast Belfast Northern Ireland

5. Belgian Cancer Registry Brussels Belgium

6. PHARMO Institute for Drug Outcomes Research Utrecht The Netherlands

Funder

Ferring

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/fcp.12454

Reference50 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

2. The Epidemiology of urological cancer 2001–2013

3. Androgen deprivation therapy in the treatment of advanced prostate cancer;Perlmutter M.A.;Rev. Urol.,2007

4. Management of High-Risk Populations with Locally Advanced Prostate Cancer

5. Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan;Prostate Cancer and Prostatic Diseases;2022-06-03

2. Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases;International Journal of Cancer;2020-11-23

3. Overview of French databases available for studying anticancer drugs in real‐life setting;Fundamental & Clinical Pharmacology;2020-08-17